Mundipharma
Diana Wei is a highly experienced professional in the field of pharmacovigilance and medical safety, currently serving as the Senior Pharmacovigilance Manager and Safety Cluster Lead JPAK at Mundipharma since January 2023. Prior to this role, Diana worked as a Senior Medical and Product Safety Associate at Blackmores Group from March 2020 to October 2022, and held the position of Pharmacist Trainer and Assessor at the Pharmaceutical Society of Australia from July 2019 to March 2020. Additionally, Diana gained experience as a Medical Services Associate at Actelion (now Janssen Pulmonary Hypertension) from January 2018 to July 2019. Educational qualifications include a degree in Medical Science from the University of Sydney and a Master of Pharmacy from the University of Newcastle, along with training in the Medicines Australia Code of Conduct from the University of Tasmania.
This person is not in any teams
This person is not in any offices
Mundipharma
5 followers
The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries. In Europe, the network employees more than 2,000 employees from R&D to manufacturing & supply and commercial, and with revenues in excess of €1 billion. At Mundipharma we strive for one high performing and learning environment where individuals can make a real difference. We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. We have built a European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as diabetes, respiratory, oncology, pain and biosimilars.